RCS - Renalytix PLC - Renalytix to Present at Growth Stock Conference

RenalytixAnnouncement

08/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220608:nRSH0740Oa&default-theme=true

RNS Number : 0740O  Renalytix PLC  08 June 2022

 

 

Renalytix to Present at 42(nd) Annual William Blair Growth Stock Conference

 

NEW YORK and SALT LAKE CITY, June 8, 2022 -- Renalytix plc (NASDAQ: RNLX)
(LSE: RENX) today announced the Company will present at the 42(nd) Annual
William Blair Growth Stock Conference on Thursday, June 9 at 2:00 p.m. CT.
Interested parties may access a live and archived webcast of the presentation
on the "Investors" section of the company website at investors.renalytix.com
(https://www.globenewswire.com/Tracker?data=IEpuTa_lMoky_OL8zF6gZH69vpa1u8C5tKLPdZ4Ss4aeZyrBGNAf-dv5yeXxWqZyFupIGoCeP6F2Iyi5LLDAOoJq6vUt7m8dBF8EDwYSHxBZ2EPV0g19aT51ScWJ2D6fYTP7_byuSFhnErW1T_LQtKiuiHqKgbTOAhi0WhfoVBNHqjbyxECd0Dnq0vna1UgtlNJw5jbTnNELhQJGwX2f68gvmUIetpg2T9eOG9rIcuI1SmOsARWSq8tdbGSEnNdTAeHpeBMAU4ga9wvXfMoMcg==)
.

 

 

For further information, please contact:

 

 Renalytix plc                                                                     www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                                             Via Walbrook PR

 Stifel (Nominated Adviser, Joint Broker)                                          Tel: 020 7710 7600
 Alex Price / Nicholas Moore

 Investec Bank plc (Joint Broker)                                                  Tel: 020 7597 4000
 Gary Clarence / Daniel Adams

 Walbrook PR Limited        Tel: 020 7933 8780 or renalytix@walbrookpr.com
                            (mailto:renalytix@walbrookpr.com)
 Paul McManus / Lianne Applegarth / Alice Woodings     Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

 CapComm Partners                                      Tel: 415-389-6400 or investors@renalytix.com
 Peter DeNardo

 

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis(TM) for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory-developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D with early
CKD stages 1-3. We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(http://www.renalytix.com/) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFRMMTMTIMTPT